Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Functionalised Nanomaterials for Eradication of Cscs, a Promising Approach for Overcoming Tumour Heterogeneity Publisher Pubmed



Farahmand L1 ; Darvishi B1 ; Salehi M1 ; Samadi Kouchaksaraei S1 ; Majidzadeha K1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  2. 2. Tasnim Biotechnology Research Center, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran

Source: Journal of Drug Targeting Published:2018


Abstract

Today, intratumoural heterogeneity has been recognised as one of the main causes of cancer treatment failure and drug resistance development through which multiple mechanisms are simultaneously involved. From the broad diversity of cells presented in tumour microenvironment, owing to their proliferative potential and longevity, cancer stem cells (CSCs), are the main cell subpopulation involved in tumour development, propagation, metastatic dissemination and induction of intratumoural heterogeneity. Accordingly, selective targeting and eradication of CSCs may represent a promising approach for cancer therapy and evading drug resistance development. Nanotechnology is an attractive outgrowing field in medicine due to its promising capabilities in solving several obstacles associated with conventional chemotherapy agents including poor solubility, lack of selectivity and high systemic toxicity. Accordingly, multiple types of nanocarriers have been successfully developed for improving selective delivery and reducing non-selective toxicities of CSC-specific chemotherapy agents. In Current review, we mostly focus on examining the role of CSCs in development of intratumoral heterogeneity and introducing recently developed nano delivery systems for more efficient targeting and eradication of them. © 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Other Related Docs
10. Epigenetic of Retinoic Acid Receptor ß2 Gene in Breast Cancer, Epigenetics Territory and Cancer (2015)
12. Application of Nano-Radiosensitizers in Combination Cancer Therapy, Bioengineering and Translational Medicine (2023)
16. Glance Into Cancer Stem Cells, Journal of Kerman University of Medical Sciences (2016)
25. Non-Coding Rnas and Glioma: Focus on Cancer Stem Cells, Molecular Therapy Oncolytics (2022)
30. Cancer Stem Cells, Stem Cells in Urology (2020)
37. Smart Internal Stimulus-Responsive Nanocarriers for Drug and Gene Delivery, Smart internal stimulus-responsive nanocarriers for drug and gene delivery (2015)
46. Recent Advances in Sirna Delivery Systems for Prostate Cancer Therapy, Current Pharmaceutical Biotechnology (2022)